FASN and breast carcinoma: The pooled analysis indicated, with significant heterogeneity (I2 = 70.4%; P = 0.017), that increased FASN expression was not associated with the poor DFS/RFS of breast cancer patients (HR, 1.65; 95% CI, 0.61-4.43; P = 0.323) (Figure 2).